This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
Development PipelineSEA-CD40
an investigational sugar-engineered antibody directed to the immune-activating receptor CD40
The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Clinical Trials
SGNS40-002: Melanoma and NSCLC (SEA-CD40 ± anti-PD1 ± chemotherapy)
-
Phase 1
-
Phase 2
-
Phase 3
SGNS40-001: Advanced solid tumors and lymphomas (SEA-CD40 ± anti-PD1 ± chemotherapy)
-
Phase 1
-
Phase 2
-
Phase 3
Program Resources

High-level synopsis of SEA-CD40 and ongoing clinical trials

Detailed information about SEA-CD40 clinical trials
Related Links